

Michael E Goldberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8765482/publications.pdf>

Version: 2024-02-01

11
papers

1,701
citations

1040056

9
h-index

1372567

10
g-index

12
all docs

12
docs citations

12
times ranked

3572
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational Signatures of Replication Timing and Epigenetic Modification Persist through the Global Divergence of Mutation Spectra across the Great Ape Phylogeny. <i>Genome Biology and Evolution</i> , 2022, 14, .	2.5	21
2	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
3	Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 292-303.	4.1	9
4	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. <i>PLoS ONE</i> , 2020, 15, e0231999.	2.5	36
5	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
6	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. <i>PLoS ONE</i> , 2018, 13, e0208097.	2.5	17
7	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	9.4	1,108
8	Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. <i>Genome Medicine</i> , 2017, 9, 16.	8.2	50
9	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. <i>Cancer Research</i> , 2017, 77, 2464-2475.	0.9	93
10	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. <i>Lung Cancer</i> , 2017, 108, 228-231.	2.0	125
11	Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. <i>Cancer Research</i> , 2017, 77, 6313-6320.	0.9	22